Cardiol Therapeutics Inc.
No enriched coverage for $CRDL in the last 7 days.
No SEC Form 4 filings for $CRDL in the last 30 days.
See all $CRDL insider activity →The article compares small-cap medical stocks Aptorum Group (NASDAQ:APM) and Cardiol Therapeutics (NASDAQ:CRDL). It cites beta values of 0.3 for APM and 0.77 for CRDL, institutional ownership of 3.8% vs 12.5%, and insider ownership of 64.0% vs 5.3%. MarketBeat data shows CRDL consensus target price of $8.50 (upside 553.85%). It also states APM has higher revenue and earnings.
Cardiol Therapeutics Inc. announced the results of its 2025 Annual General Meeting of Shareholders, where all Management resolutions were approved. Dr. Timothy Garnett was elected to the Board of Directors, bringing extensive drug development and commercial expertise to the company. The company also provided updates on its clinical trials for CardiolRx™ in recurrent pericarditis and acute myocarditis, and the development of CRD-38 for heart failure.
Innovation is at its peak in the Zacks Medical-Drugs industry. AKBA, IRWD, PYXS, CRDL and PSTV may prove to be good additions to one's portfolio.
Recent CRDL coverage spans financial news and sector analysis.
The main tradable element is the stated analyst upside versus APM, which can influence speculative flows in small-cap biotech.
The positive corporate developments and ongoing clinical trials suggest potential upside for CRDL shares, especially if trial results are favorable.
CRDL remains neutral; limited immediate trading signals.
The neutral coverage on Cardiol Therapeutics (CRDL) suggests limited short-term price movement.
alphai scores every news story that mentions CRDL with an AI model for sentiment and relevance, and aggregates insider trades from Cardiol Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
The article compares small-cap medical stocks Aptorum Group (NASDAQ:APM) and Cardiol Therapeutics (NASDAQ:CRDL). It cites beta values of 0.3 for APM and 0.77 for CRDL, institutional ownership of 3.8% vs 12.5%, and insider ownership of 64.0% vs 5.3%. MarketBeat data shows CRDL consensus target price of $8.50 (upside 553.85%). It also states APM has higher revenue and earnings.
4 min readCardiol Therapeutics Inc. announced the results of its 2025 Annual General Meeting of Shareholders, where all Management resolutions were approved. Dr. Timothy Garnett was elected to the Board of Directors, bringing extensive drug development and commercial expertise to the company. The company also provided updates on its clinical trials for CardiolRx™ in recurrent pericarditis and acute myocarditis, and the development of CRD-38 for heart failure.
4 min readInnovation is at its peak in the Zacks Medical-Drugs industry. AKBA, IRWD, PYXS, CRDL and PSTV may prove to be good additions to one's portfolio.
4 min readTop Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
4 min read
